Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis


Options:
A: Number of Participants Attaining a 90 Percent Reduction in PASI From Baseline (PASI 90) - ITT (112 and 140 days)
B: Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28 (Baseline, 16 hours post-dose on Day 28); Number of Participants With Change From Baseline in Physical Examinations (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28 (Baseline, 16 hours post-dose on Day 28); Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28 (Baseline, 16 hours post-dose on Day 28); Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Number of Adverse Events (AEs) According to Severity (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Number of Participants With Laboratory Abnormalities (SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37); Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1 (Baseline, 24 hours post-dose on Day 1); Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10 (Baseline, 16 hours post-dose on Day 10); Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28 (Baseline, 16 hours post-dose on Day 28); Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1); Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841 (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1); Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 (pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1)
C: Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12 (12 Weeks); Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12 (12 Weeks)
D: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12 (Week 12); Participants With IGA Mod 2011 0 or 1 at Week 12 (Week 12)

Answer: C